AquaBounty Reviewing FDA’s Amended Environmental Assessment
AquaBounty is once again on a rollercoaster with the U.S. Food and Drug Administration (FDA). On November 16 the FDA announced the “availability of a draft amended Environmental Assessment (EA) for an approved application concerning Atlantic salmon with an intentionally altered genome, and a subsequent virtual public meeting to obtain public input on the draft amended EA.”
The FDA had approved an application for AquaBounty’s AquAdvantage Salmon (AAS), which contains an intentional genomic alteration, back in November 2015. As part of the process of evaluating the application...
To Read Full Story Login Below.